Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovita Biological Technology Co (SHSE:688253) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Innovita Biological Technology Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥6,502.1 Mil.
Innovita Biological Technology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥52.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co EV-to-EBIT Related Terms
Innovita Biological Technology Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co EV-to-EBIT Chart
SHSE:688253 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Innovita Biological Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovita Biological Technology Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovita Biological Technology Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Innovita Biological Technology Co's EV-to-EBIT falls into.
Innovita Biological Technology Co's current Enterprise Value is ¥5,700.8 Mil.
Innovita Biological Technology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥52.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co (SHSE:688253) has a EV-to-EBIT of 108.89 as of Sep. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Innovita Biological Technology Co and its competitors. This is 805% above median its historical median of 12.03. Over the past decade, Innovita Biological Technology Co's EV-to-EBIT has ranged from 4.63 to 149.79. According to the industry distribution chart, Innovita Biological Technology Co ranks #345 out of 369 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Innovita Biological Technology Co's EV-to-EBIT too high?
Innovita Biological Technology Co's current EV-to-EBIT of 108.89 is 805% above median its 10-year median of 12.03. Over the past 10 years, this metric has ranged from a low of 4.63 to a high of 149.79. The Biotechnology industry median EV-to-EBIT is 14.40. Innovita Biological Technology Co's value of 108.89 is 656.2% above this industry median. Based on the distribution chart, Innovita Biological Technology Co ranks #345 out of 369 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innovita Biological Technology Co has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innovita Biological Technology Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovita Biological Technology Co ranks #345 out of 369 companies for EV-to-EBIT. This places Innovita Biological Technology Co in the lower half of its industry. The industry median EV-to-EBIT is 14.40. Innovita Biological Technology Co's value of 108.89 is 656.2% above this benchmark. Historically, Innovita Biological Technology Co's own EV-to-EBIT has ranged from 4.63 to 149.79 over the past decade. While the company's 10-year median is 12.03 vs. the industry median of 14.40, Innovita Biological Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.40, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovita Biological Technology Co's current EV-to-EBIT of 108.89 is 656.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Innovita Biological Technology Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovita Biological Technology Co's current EV-to-EBIT is 108.89, which is 805% above median its own 10-year median of 12.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovita Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Innovita Biological Technology Co (SHSE:688253) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥20.34, compared to a current price of ¥54.43 — trading 167.6% above its estimated fair value. The current EV-to-EBIT is 108.89, which is 805% above median its 10-year median of 12.03 and 656.2% above the Biotechnology industry median of 14.40. Innovita Biological Technology Co's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Innovita Biological Technology Co (SHSE:688253), the current EV-to-EBIT is 108.89 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovita Biological Technology Co (SHSE:688253) Overvalued in 2026?
Based on GuruFocus' analysis, Innovita Biological Technology Co stock appears to be overvalued.
The current stock price of ¥54.43 is trading 167.6% above its estimated GF Value™ of ¥20.34.
GuruFocus considers Innovita Biological Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688253:
EV-to-EBIT: 108.89 (805% above median its 10-year median of 12.03)
GF Value™: ¥20.34 vs. price of ¥54.43 (167.6% above fair value)
Industry Position: 656.2% above the Biotechnology median (#345 of 369)
No single metric tells the full story. See the SHSE:688253 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production, and sales of POCT in vitro diagnostic products.
59GF Score
Get the complete analysis for SHSE:688253
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688253 has been successfully added to your 
